Interview with Aihua Pan, Chairman, SinoBioway Group
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
Address: PKU Biocity No. 39 ShangDiXi Lu, Haidian, Beijing, P.R. China
Tel: 86 10 8289 0924
SinoBioway Group Co., Ltd. was founded in 1992 and is one of the three major industry groups of Beijing University. It is mainly engaged in bio-industry development and the establishment of bio-economic systems with a focus on investment in three main areas: bio-medicine, bio-agriculture and bio-services. After more than ten years of dedication, the group has become China’s most influential and modern bio-enterprise.
The group now owns three main facilities: Beijing University Biological City, Beijing University Biological Park at Xiamen and Guangzhou Liuxi Biological Bay. Additionally, the group operates multiple holding subsidiaries such as Beijing Sinovac Biotech Co., Ltd., Xiamen Bioway-PKU Biotech Co., Ltd., Guangzhou Weiming Biotech Co., Ltd., Weiming Nature Unity Chinese Medicine Co., Ltd. and Beijing Weiming Kaituo Agricultural Biotech Ltd.
The main products of SinoBioway include an injection of mouse-nerve growth factor (Nobex ®), an inactivated hepatitis A vaccine (Healive ®), a hepatitis B vaccine (Bilive ®), anti-flu vaccines (Anflu ®, Panflu ®, and Panflu.1 ®), as well as hundreds of kinds of Chinese medicinal granules. The group now has established a fairly complete R & D system with centers for: Bio-Pharmaceutical Research, Vaccine Research, National Crop Molecular Design, Bio-Intelligence Research, Bio-Economic Research. It operates various institutions and R & D platforms while employing a group of outstanding research personnel.
Having researched mainly for the bio-economy, biological drugs (generic drugs and peptide drugs), human vaccines, modern Chinese medicine, molecular crop breeding, biomass energy and bio-intelligence technology, the group has achieved a series of major breakthroughs. These include the successful development and production of the world’s first drug treatment of traumatic nerve injury – the “nerve growth factor”, the world’s first “inactivated vaccine targeting SARS virus”, and China’s first “human-use influenza vaccine”. The world’s first influenza A (H1N1) vaccine -Panflu.1 ® was successfully produced on September 3, 2009. The group has initiated the world’s first “bio-economy incubator” (an efficient R & D system of new drugs), established a theoretical system of bio-economy, created an economic bio-restructuring model, and carried out a preliminary study of bio-industry development ideas suitable for China’s national conditions.
SinoBioway has engaged in corporate restructuring and through government guidance has shifted to a market approach. At the moment, the group has formed five industry groups on the basis of existing enterprises which include: vaccines, traditional Chinese medicine, bio-pharmaceuticals, modern agriculture and biological services. Through forming bio-economic systems in the industrial, R & D and financial arena, the group aims to build SinoBioway into a flagship company for the bio-economy era.
vaccines, traditional Chinese medicine, bio-pharmaceuticals
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
The pharma industry tends to see a lot of personnel movement, particularly at management levels, but since the Chinese market started heating up a few years ago, the labour market…
Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually…
Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs…
Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the…
The rate of diabetes in China has exploded: the number of diabetic patients has surpassed 100 million and is expected to increase to 150 million by 2040. Dr Qinghua Wang,…
Dr Dong Wei, CEO of EdiGene, shares the fascinating story behind the establishment of EdiGene, including his close relationship with EdiGene founder Professor Wensheng Wei; the insights he bring from…
Speaking in May 2019, Dr Dajun Yang, chairman, executive director and CEO of Ascentage Pharma, shares the company’s top highlights over the past decade; their strong product pipeline and portfolio…
Mark Lotter, founder and CEO of Nuance Biotech, explains why he decided to return to the China market to establish Nuance Biotech, two years after his retirement. He also shares…
Michael Zhang, chairman of Peijia Medical, shares Peijia Medical’s mission to become a two-platform medical device company as well as the partner of choice for physicians in China and globally.…
PharmaBoardroom recently analysed the contents of 10 interviews conducted with country managers at multinational pharma companies in China. We found some underlying themes present in the majority of the interviews,…
Dr. Zhang Yu, CEO of Aeon Therapeutics, shares the unique journey that motivated him to establish Aeon Therapeutics, as a joint venture of Chinese VcanBio and US-based Eureka Therapeutics, to…
With proactive government support and an increasingly specialised workforce, China has become one of the leading nations in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, along with the…
See our Cookie Privacy Policy Here
